Related Experiment Video

Updated: Jun 6, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

A novel treatment strategy for type 2 diabetes: Targeting glucose variability and β-cell failure

Jia Deng1, Bochu Wang, Yang Cao

  • 1Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, PR China.

Medical Hypotheses
|November 13, 2010
PubMed

Insights

This study proposes a novel dual-target drug delivery system for type 2 diabetes management. It aims to improve blood glucose control and repair beta-cell function for better homeostasis.

Area of Science:

  • Biomedical Engineering
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes management faces challenges with poor blood glucose control and side effects.
  • Blood glucose variability is linked to severe diabetic complications.
  • Reversible beta-cell failure in early type 2 diabetes presents a therapeutic target.

Purpose of the Study:

  • To propose a novel treatment strategy targeting both blood glucose control and beta-cell repair in type 2 diabetes.
  • To introduce an intelligent double-target drug delivery system for enhanced therapeutic outcomes.

Main Methods:

  • Development of a dual-responsive drug delivery system with glucose-sensitive gates.
  • Incorporation of a controlled-release system for hypoglycemic agents.
  • Integration of a sustained-release osmotic pump for beta-cell repair drugs.

Main Results:

  • The proposed system utilizes dual-responsive functional gates for targeted drug release.
  • Hypoglycemic agents are released in response to glucose levels.
  • Drugs to repair beta-cells are delivered via a sustained-release mechanism.

Conclusions:

  • The novel drug delivery system offers a potential new early therapeutic strategy for type 2 diabetes.
  • This approach aims to improve blood glucose homeostasis by addressing two key pathological aspects.
  • The dual-target system may overcome limitations of current type 2 diabetes treatments.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...